immune system
• reduced proliferation of T regulatory cells in the thymus but not spleen or lymph nodes
|
• at 2 to 5 months with accumulation of activated T cells
|
• in the lymph node
|
• in the thymus but not lymph node or spleens
• in the thymus and periphery of female mice at 3 months
|
• in the lymph nodes and spleen at 2 to 5 months
• with IFN-gamma expression
|
• at 2 to 5 months with accumulation of activated T cells
|
• by 8 to 12 weeks with crusting eyelids, facial hair loss, which progressed to hair loss on the trunk, skin lesions, an ill appearance, ruffled fur, hunching and reduced movements
• however, CD28-sufficient regulatory T cells prevent the autoimmune disease development
|
• 20 days after immunization, mice treated with rMOG/CFA plus pertussis toxin exhibit increased clinical score and fail to recover compared with wild-type mice
|
• at 2 to 5 months
|
integument
• at 2 to 5 months
|
• facial hair loss, which progressed to hair loss on the trunk by 8 to 12 weeks
|
ruffled hair
(
J:194503
)
• by 8 to 12 weeks
|
skin lesions
(
J:194503
)
• by 8 to 12 weeks
|
behavior/neurological
• by 8 to 12 weeks
|
• by 8 to 12 weeks
|
vision/eye
• crusting by 8 to 12 weeks
|
hematopoietic system
• reduced proliferation of T regulatory cells in the thymus but not spleen or lymph nodes
|
• at 2 to 5 months with accumulation of activated T cells
|
• in the lymph node
|
• in the thymus but not lymph node or spleens
• in the thymus and periphery of female mice at 3 months
|
• in the lymph nodes and spleen at 2 to 5 months
• with IFN-gamma expression
|
growth/size/body
• at 2 to 5 months with accumulation of activated T cells
|
cellular
• reduced proliferation of T regulatory cells in the thymus but not spleen or lymph nodes
|